Modiin, Israel (ots/PRNewswire) - The trial assesses the safety and efficacy of the IUB(TM) SEAD(TM), a disruptive treatment for AUB. In this study, 50% of the participating patients have reached the End of the Study point, demonstrating a significant reduction in bleeding, avoiding the need to undergo invasive uterine ablation procedures or even a hysterectomy
OCON Healthcare, a women's health company which develops, manufactures and...
quelle: OTS